1. Home
  2. QFIN vs RCUS Comparison

QFIN vs RCUS Comparison

Compare QFIN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$15.06

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$22.59

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
RCUS
Founded
2016
2015
Country
China
United States
Employees
3527
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.8B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
QFIN
RCUS
Price
$15.06
$22.59
Analyst Decision
Buy
Buy
Analyst Count
2
10
Target Price
$36.85
$30.30
AVG Volume (30 Days)
1.3M
1.1M
Earning Date
01-01-0001
05-28-2026
Dividend Yield
10.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$247,000,000.00
Revenue This Year
$16.96
N/A
Revenue Next Year
N/A
$19.94
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.04
$6.79
52 Week High
$48.94
$26.40

Technical Indicators

Market Signals
Indicator
QFIN
RCUS
Relative Strength Index (RSI) 44.51 57.16
Support Level $14.79 $20.35
Resistance Level $17.08 $24.16
Average True Range (ATR) 0.63 1.38
MACD 0.08 0.44
Stochastic Oscillator 49.72 65.46

Price Performance

Historical Comparison
QFIN
RCUS

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: